Key market opportunities include the growth of precision medicine, AI integration in drug discovery, increased R&D in ...

Mild to moderate diarrhea was the most common (55%) treatment-related adverse event. The maximum-tolerated dose was 400 mg bid continuous. Dose-limiting toxicities were grade 3 diarrhea and fatigue at ...

Voronoi and Voronoi Bio Inc. have patented serine/threonine-protein kinase B-raf (BRAF), Raf kinase and Raf kinase B (V600E mutant) inhibitors reported to be useful for the treatment of cancer.

Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial RKIP expression in primary CRCs correlates with overall and ...

Erasca, Inc. focuses on developing novel targeted therapies for solid tumors, particularly through the RAS/MAP kinase pathway, with a promising yet early-stage pipeline. The company’s lead program, ...